Clinical TrialsThe FDA placed a clinical hold on zelnecirnon trials due to a case of liver failure, leading to the closure of Phase 2 trials.
Financial PerformanceThe company announced a 40% workforce reduction to conserve cash resources, indicating financial strain.
Regulatory ApprovalRisks include negative proof-of-concept efficacy data for zelnecirnon in Phase 2b testing in AD, failure to advance zelnecirnon into pivotal testing in allergic conditions, and inability to secure regulatory approval for zelnecirnon.